Why the study?
Does roxithromycin prevent death and re-infarction in patients with acute non-Q-wave coronary syndromes?
Does roxithromycin prevent death and re-infarction in patients with acute non-Q-wave coronary syndromes?
In patients with acute non-Q-wave coronary syndromes, roxithromycin may provide clinical benefit by preventing death and re-infarction at 6 months.
Answers are grounded in this paper and cite their sources.
May support extended roxithromycin benefit in non-Q-wave ACS; hypothesis-generating and requires randomized confirmation.
In this pilot trial, roxithromycin appears to extend the clinical benefit of preventing death and re-infarction for at least 6 months after initial treatment.
No takes yet. Share an insight, caveat, or question.
Enrique Gurfinkel (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: